IS5341A - Samsett meðferð sem inniheldur atórvastatin og þrýstingslækkandi miðil - Google Patents

Samsett meðferð sem inniheldur atórvastatin og þrýstingslækkandi miðil

Info

Publication number
IS5341A
IS5341A IS5341A IS5341A IS5341A IS 5341 A IS5341 A IS 5341A IS 5341 A IS5341 A IS 5341A IS 5341 A IS5341 A IS 5341A IS 5341 A IS5341 A IS 5341A
Authority
IS
Iceland
Prior art keywords
combination therapy
antihypertensive agent
therapy containing
containing atorvastatin
atorvastatin
Prior art date
Application number
IS5341A
Other languages
English (en)
Inventor
Andrew Donald Scott Robert
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of IS5341A publication Critical patent/IS5341A/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Iron Core Of Rotating Electric Machines (AREA)
  • Pyrrole Compounds (AREA)
IS5341A 1997-08-29 2000-01-14 Samsett meðferð sem inniheldur atórvastatin og þrýstingslækkandi miðil IS5341A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5727697P 1997-08-29 1997-08-29
PCT/IB1998/001230 WO1999011260A1 (en) 1997-08-29 1998-08-11 Combination therapy comprising atorvastatin and an antihypertensive agent

Publications (1)

Publication Number Publication Date
IS5341A true IS5341A (is) 2000-01-14

Family

ID=22009602

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5341A IS5341A (is) 1997-08-29 2000-01-14 Samsett meðferð sem inniheldur atórvastatin og þrýstingslækkandi miðil

Country Status (41)

Country Link
US (2) US20020099046A1 (is)
EP (1) EP1009400B1 (is)
JP (2) JP2001514223A (is)
KR (3) KR20040106591A (is)
CN (3) CN1473566A (is)
AP (1) AP1191A (is)
AR (1) AR016399A1 (is)
AT (1) ATE285767T1 (is)
AU (1) AU740424B2 (is)
BG (1) BG64724B1 (is)
BR (1) BR9811556A (is)
CA (1) CA2296723A1 (is)
CO (1) CO4970724A1 (is)
DE (1) DE69828413T2 (is)
DZ (1) DZ2595A1 (is)
EA (1) EA200000012A1 (is)
EG (1) EG24678A (is)
ES (1) ES2234134T3 (is)
GT (1) GT199800126A (is)
HR (1) HRP980474A2 (is)
HU (1) HUP0004318A3 (is)
ID (1) ID24118A (is)
IL (2) IL133962A0 (is)
IS (1) IS5341A (is)
MA (1) MA26536A1 (is)
MY (1) MY121008A (is)
NO (1) NO323987B1 (is)
NZ (2) NZ530630A (is)
OA (1) OA11291A (is)
PA (1) PA8457901A1 (is)
PE (1) PE107099A1 (is)
PL (1) PL339091A1 (is)
PT (1) PT1009400E (is)
SA (1) SA98190603B1 (is)
SK (1) SK1432000A3 (is)
TN (1) TNSN98155A1 (is)
TR (1) TR200000563T2 (is)
UY (1) UY25155A1 (is)
WO (1) WO1999011260A1 (is)
YU (1) YU2000A (is)
ZA (1) ZA987839B (is)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT656786E (pt) 1992-05-19 2004-11-30 Novogen Res Pty Ltd Utilizacao de extractos do fitoestrogenio isoflavona de soja ou trevo
US6642268B2 (en) 1994-09-13 2003-11-04 G.D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
US6262277B1 (en) 1994-09-13 2001-07-17 G.D. Searle And Company Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
AUPO203996A0 (en) 1996-08-30 1996-09-26 Novogen Research Pty Ltd Therapeutic uses
GT199800127A (es) * 1997-08-29 2000-02-01 Combinaciones terapeuticas.
BR9815745A (pt) * 1998-03-17 2000-11-14 Warner Lambert Co Combinações de inibidor de metaloproteinase de matriz estatina
WO2000038721A1 (en) 1998-12-23 2000-07-06 G.D. Searle Llc Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acid derivatives for cardiovascular indications
AU2007200367B2 (en) * 1999-02-06 2010-04-08 Astrazeneca Ab Use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy
GB0001662D0 (en) 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
CN1268331C (zh) 1999-08-30 2006-08-09 萨诺费－阿文蒂斯德国有限公司 肾素－血管紧张素系统抑制剂在制备预防心血管疾病的药物中的用途
AUPQ266199A0 (en) 1999-09-06 1999-09-30 Novogen Research Pty Ltd Compositions and therapeutic methods involving isoflavones and analogues thereof
DE19944803A1 (de) * 1999-09-20 2001-03-29 Bayer Ag Kombination von Dihydropyridinverbindungen und HMG-CoA-Reduktase-Inhibitoren und ihre Verwendung in Arzneimitteln
EP1218017B1 (en) 1999-09-24 2005-11-16 Vasogen Ireland Limited Combination of a statin and ex-vivo treated blood for treating atherosclerosis
FR2803525B1 (fr) * 2000-01-06 2002-05-03 Sod Conseils Rech Applic Inhibiteur de la transduction des signaux des proteines g heterotrimeriques associe a un agent anti-hypertenseur dans le traitement de l'hypertension arterielle
AR030414A1 (es) * 2000-04-03 2003-08-20 Astrazeneca Ab Combinacion farmaceutica que comprende un beta bloqueante y un inhibidor de hmg-coa reductasa , formulacion farmaceutica, equipo transportable de partes , uso de esta combinacion y de esta formulacion para preparar medicamentos
GB2361185A (en) 2000-04-10 2001-10-17 Nicholas J Wald Pharmaceutical formulation for the prevention of cardiovascular disease
SE0002354D0 (sv) * 2000-06-22 2000-06-22 Astrazeneca Ab New formulation
ES2309090T3 (es) 2000-07-19 2008-12-16 Novartis Ag Sales de valsartan.
CA2420844A1 (en) * 2000-08-30 2003-02-28 Sankyo Company, Limited Medicinal compositions for preventing or treating heart failure
US7018649B2 (en) * 2000-10-23 2006-03-28 Euro-Celtique, S.A. Felodipine transdermal device and methods
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
AUPR255401A0 (en) * 2001-01-16 2001-02-08 Novogen Research Pty Ltd Regulation of lipids and/or bone density and compositions therefor
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
PL205343B1 (pl) 2001-01-26 2010-04-30 Schering Corp Zastosowanie inhibitora wchłaniania sterolu
ATE348649T1 (de) 2001-01-26 2007-01-15 Schering Corp Kombinationen von einem hemmer der sterol- absorption und einem ppar-aktivator zur behandlung von kardiovaskulären indikationen
AUPR363301A0 (en) 2001-03-08 2001-04-05 Novogen Research Pty Ltd Dimeric isoflavones
KR20040023660A (ko) * 2001-07-19 2004-03-18 파마시아 코포레이션 알도스테론 수용체 길항제 및 ｈｍｇ ｃｏａ 환원효소억제제의 병용물
PE20030324A1 (es) * 2001-07-31 2003-04-03 Warner Lambert Co Composiciones farmaceuticas de amlodipina y atorvastatina
US6852737B2 (en) * 2001-08-06 2005-02-08 Recordati Ireland Limited Crude and crystalline forms of lercanidipine hydrochloride
CA2460340C (en) 2001-09-21 2011-02-15 Schering Corporation Methods and therapeutic combinations for the treatment of xanthoma using sterol absorption inhibitors
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
WO2003061604A2 (en) 2002-01-17 2003-07-31 Pharmacia Corporation Novel alkyl/aryl hydroxy or keto thiepines.
WO2004000353A1 (en) * 2002-06-20 2003-12-31 The Governors Of The University Of Alberta Dichloroacetate in combination with cardioprotective or hemodynamic drugs
EP1539140A4 (en) * 2002-06-27 2005-12-07 Sb Pharmco Inc CARVEDILOLHYDOBROMID
WO2004002419A2 (en) * 2002-06-27 2004-01-08 Sb Pharmco Puerto Rico Inc. Carvedilol phosphate salts and/or solvates thereof, correspondinq compositions, and/or methods of treatment
US7071210B2 (en) * 2002-07-02 2006-07-04 Pfizer Inc. CETP inhibitors in combination with antihypertensive agents and uses thereof
US20040053842A1 (en) * 2002-07-02 2004-03-18 Pfizer Inc. Methods of treatment with CETP inhibitors and antihypertensive agents
GB0221579D0 (en) * 2002-09-17 2002-10-23 Pfizer Ltd Combinations of atorvastatin and, adrenergic receptor antagonists
JP2006504800A (ja) * 2002-10-16 2006-02-09 レコーダチ アイルランド リミテッド リシノプリル／レルカニジピンの組み合わせ治療
CA2504878A1 (en) 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorption inhibitors for the treatment of demyelination
ES2311806T3 (es) 2003-03-07 2009-02-16 Schering Corporation Compuesto de azetidinona sustituidos, fornulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
US7192944B2 (en) 2003-03-07 2007-03-20 Schering Corp. Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
ES2318274T3 (es) 2003-03-07 2009-05-01 Schering Corporation Compuestos de azetidinona sustituida, formulaciones y uso de los mismos para el tratamiento de hipercolesterolemia.
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
WO2005051325A2 (en) * 2003-11-25 2005-06-09 Sb Pharmco Puerto Rico Inc. Carvedilol compositions methods of treatment and delivery
EP1686986A4 (en) * 2003-11-25 2009-05-27 Sb Pharmco Inc CARVEDILOL SALTS, CORRESPONDING COMPOSITIONS, METHODS OF ADMINISTRATION AND / OR TREATMENT
ES2662903T3 (es) * 2003-11-25 2018-04-10 Smithkline Beecham (Cork) Limited Base libre de carvedilol, sales, formas anhidras o solvato de la misma, composiciones farmacéuticas correspondientes, formulaciones de liberación controlada, y procedimientos de tratamiento o administración
KR20050092519A (ko) * 2004-03-16 2005-09-22 화이자 인코포레이티드 아토르바스타틴 및 α1-아드레날린성 수용체 길항제의 조합
EP1734958A1 (en) * 2004-04-06 2006-12-27 Merck & Co., Inc. Methods for the treatment of hypertension
AU2005249794A1 (en) 2004-06-04 2005-12-15 Teva Pharmaceutical Industries, Ltd. Pharmaceutical composition containing irbesartan
EP2404605B1 (en) 2004-08-25 2015-04-22 Essentialis, Inc. Pharmaceutical formulations of potassium ATP channel openers and uses thereof
JP2008530153A (ja) * 2005-02-17 2008-08-07 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ マニジピンおよびスタチンの治療における組み合わせ
CN101415425B (zh) * 2006-03-29 2014-11-26 兴和株式会社 甘油三酯降低剂和高胰岛素血症改善剂
MX2009004681A (es) * 2006-10-30 2009-08-19 Hanall Pharmaceutical Co Ltd Composicion compleja de liberacion controlada que comprende bloqueadores del receptor de angiotensina ii e inhibidores de hmg-coa-reductasa.
CN102065847A (zh) 2008-04-29 2011-05-18 韩诺生物制约株式会社 含有血管紧张素-ⅱ受体阻断剂的药物制剂
CZ301299B6 (cs) * 2008-11-24 2010-01-06 Zentiva, A.S. Pevná farmaceutická kompozice s úcinnými látkami atorvastatinem a telmisartanem
CA2749903C (en) * 2009-01-23 2016-09-06 Jae Hyun Park Solid pharmaceutical composition comprising amlodipine and losartan and process for producing same
SI23149A (sl) * 2009-09-21 2011-03-31 Silverstone Pharma Nove benzatinske soli ACE inhibitorjev, postopek za njihovo pripravo in njihova uporaba za zdravljenje kardiovaskularnih bolezni
RU2481124C1 (ru) * 2011-10-27 2013-05-10 Общество с ограниченной ответственностью "ВАЛЕНТА ИНТЕЛЛЕКТ" Фармацевтическая комбинация из аторвастатина и ницерголина для профилактики или лечения нарушений мозгового кровообращения
CN102671198A (zh) * 2011-12-17 2012-09-19 东莞达信生物技术有限公司 一种降压降脂复方药及其制备方法
KR20140028971A (ko) * 2012-08-31 2014-03-10 한미약품 주식회사 아토바스타틴, 이르베살탄 및 탄산마그네슘을 포함하는 이층정 복합제제
KR20140111982A (ko) * 2013-03-12 2014-09-22 주식회사 엘지생명과학 발사르탄 및 로수바스타틴 칼슘을 포함하는 복합 제제 및 이의 제조방법
CN104173420A (zh) * 2013-05-20 2014-12-03 广州诺氏刘生物科技有限公司 一种治疗急性肾衰竭的药物
MX394186B (es) 2014-10-23 2025-03-24 Arena Pharm Inc Metodo de tratamiento de afecciones relacionadas con el receptor pgi2
MX382254B (es) * 2015-06-30 2025-03-13 Hanmi Pharmaceutical Co Ltd Formulacion farmaceutica de complejo que comprende amlodipino, losartan y rosuvastatina.
FR3040303B1 (fr) * 2015-08-27 2019-04-05 Les Laboratoires Servier Suivi Par Sabine Goudeau-Wenger Composition pharmaceutique comprenant un inhibiteur de la hmg-coa reductase et un inhibiteur eca
CN105232555A (zh) * 2015-11-19 2016-01-13 哈尔滨圣吉药业股份有限公司 一种替米沙坦/瑞舒伐他汀复方制剂及其制备方法
EP3463322A4 (en) * 2016-06-02 2019-11-20 Ana Pharmaceuticals, Inc. METHOD AND COMPOSITIONS FOR TREATING HYPERCALCIURIA AND NEPHROLITHIASIS
LT4101454T (lt) 2017-01-25 2024-07-25 The George Institute for Global Health Kompozicijos, skirtos naudoti hipertenzijos gydymui
KR20220119169A (ko) 2017-03-01 2022-08-26 아레나 파마슈티칼스, 인크. Pgi2-수용체 효능제를 포함하는 조성물 및 그의 제조 방법
EP3796902A1 (en) 2018-05-16 2021-03-31 Arena Pharmaceuticals, Inc. Compositions comprising pgi2-receptor agonists and processes for the preparation thereof
CA3107616A1 (en) * 2018-07-26 2020-01-30 The George Institute for Global Health Compositions for the treatment of hypertension
CN112826937B (zh) * 2021-03-25 2022-03-22 山东大学齐鲁医院 艾地苯醌与他汀类药物联用在防治动脉粥样硬化中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4681893A (en) * 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5447922A (en) * 1994-08-24 1995-09-05 Bristol-Myers Squibb Company α-phosphonosulfinic squalene synthetase inhibitors
HUP9601808A3 (en) * 1995-07-03 2000-06-28 Sankyo Co Treatment of arteriosclerosis and xanthoma
DE69636783T2 (de) * 1995-11-02 2007-10-18 Warner-Lambert Co. Llc Verfahren und pharmazeutische zusammensetzung zur regelung der lipidkonzentration

Also Published As

Publication number Publication date
BG104075A (en) 2000-09-29
NO20000996L (no) 2000-04-27
UY25155A1 (es) 2000-12-29
EA200000012A1 (ru) 2000-08-28
TNSN98155A1 (fr) 2005-03-15
JP2005041875A (ja) 2005-02-17
BR9811556A (pt) 2000-08-22
CA2296723A1 (en) 1999-03-11
HRP980474A2 (en) 1999-06-30
AR016399A1 (es) 2001-07-04
PT1009400E (pt) 2005-02-28
DE69828413T2 (de) 2005-12-08
AU740424B2 (en) 2001-11-01
EP1009400A1 (en) 2000-06-21
EP1009400B1 (en) 2004-12-29
KR20010022477A (ko) 2001-03-15
PA8457901A1 (es) 2000-05-24
OA11291A (en) 2003-08-25
PE107099A1 (es) 1999-11-06
EG24678A (en) 2010-04-27
HUP0004318A3 (en) 2002-10-28
HUP0004318A2 (hu) 2001-05-28
NZ502280A (en) 2002-11-26
KR20040106591A (ko) 2004-12-17
CN1473567A (zh) 2004-02-11
ZA987839B (en) 2000-02-28
SK1432000A3 (en) 2000-12-11
ID24118A (id) 2000-07-06
IL133962A0 (en) 2001-04-30
PL339091A1 (en) 2000-12-04
ATE285767T1 (de) 2005-01-15
SA98190603B1 (ar) 2006-07-04
IL133962A (en) 2006-07-05
KR20030015394A (ko) 2003-02-20
YU2000A (sh) 2002-12-10
US20020099046A1 (en) 2002-07-25
ES2234134T3 (es) 2005-06-16
WO1999011260A1 (en) 1999-03-11
JP2001514223A (ja) 2001-09-11
CN1268053A (zh) 2000-09-27
AU8458998A (en) 1999-03-22
DE69828413D1 (de) 2005-02-03
MY121008A (en) 2005-12-30
NO323987B1 (no) 2007-07-30
AP1191A (en) 2003-07-19
AP9801332A0 (en) 1998-09-30
TR200000563T2 (tr) 2000-07-21
DZ2595A1 (fr) 2003-02-22
CN1473566A (zh) 2004-02-11
BG64724B1 (bg) 2006-01-31
MA26536A1 (fr) 2004-12-20
US20030199492A1 (en) 2003-10-23
GT199800126A (es) 2000-01-29
NO20000996D0 (no) 2000-02-28
CO4970724A1 (es) 2000-11-07
NZ530630A (en) 2005-05-27

Similar Documents

Publication Publication Date Title
IS5341A (is) Samsett meðferð sem inniheldur atórvastatin og þrýstingslækkandi miðil
IS5345A (is) Samsett meðferð sem inniheldur amlódipín og statín efnasambönd
DE69826683D1 (de) Therapeutische zusammensetzungen, enthaltend amlopidin und atorvastatin
DE69836008D1 (de) Zusammensetzung und behandlungsmittel
NO20032753L (no) Forbindelse og anvendelse derav
NO20003096D0 (no) Sammensetninger og fremgangsmÕter for behandling av ADD
NO983187L (no) Substituerte aza- og diazacykloheptan og -cyklooktan-forbindelse og deres anvendelse
NO20006488D0 (no) Sammensetning og anvendelse
PL335555A1 (en) Novel compounds - substituted benzamides and therapeutic agent
HUP0000963A3 (en) The use of levobupivacaine in paediatric surgery
GB9702354D0 (en) Compounds and their use
GB9704349D0 (en) Levobupivacaine and its use
DK1140952T3 (da) Phosphororganiske forbindelser og anvendelse heraf
GB9824160D0 (en) Heterocyclic compounds and their therapeutic use
NO983556L (no) Formulering og anvendelse
GB9704370D0 (en) Levobupivacaine and its use
PL341293A1 (en) Beta-lypothropin and application thereof
SI1009400T1 (en) Combination therapy comprising atorvastatin and an antihypertensive agent
EP1030608A4 (en) SURGICAL SAW AND RELATED METHODS
EP1150967A4 (en) THERAPEUTICALLY APPLICABLE CONNECTIONS AND METHODS
GB9722023D0 (en) Levobupivacaine and its use
GB9802622D0 (en) Compounds and their therapeutic use
DK1009400T3 (da) Kombinationsterapi, der omfatter atorvastatin og et antihypertensivt middel
GB9710080D0 (en) Levobupivacaine and its use
GB9715462D0 (en) levobupivacaine and its use